Curriculum · Public Health and Communicable Diseases
Diagnosis and treatment of active pulmonary tuberculosis
Causes and risk
Almost all infections with M. tuberculosis are due to inhalation of droplet nuclei 1-5 microns in diameter, aerosolized by coughing, sneezing or talking from a person with pulmonary tuberculosis; they dry while airborne and remain suspended for long periods, and the air in a room occupied by such a person may remain infectious for approximately 30 minutes even after his or her absence. Infection does not generally occur out of doors, because M. tuberculosis is killed by ultraviolet light. Prolonged exposure and multiple aerosol inocula are usually required to establish the infection, and the most important determinants are closeness of contact and infectiousness of the source.
How it is diagnosed
Unexplained cough for more than 2-3 weeks, in regions where TB is prevalent, or typical chest X-ray changes, should prompt further investigation.
Specimens in pulmonary disease are sputum, preferably 3 samples including an early morning sample, induced with nebulised hypertonic saline if the patient is not expectorating; bronchoscopy with washings or bronchoalveolar lavage; and gastric washing, mainly used for children.
- Direct microscopy of sputum is the most important first step, and is typically positive when 5000-10 000 organisms are present. Stains are Ziehl-Neelsen and auramine fluorescence.
- Culture on solid media (Lowenstein-Jensen, Middlebrook) takes 4-6 weeks; in liquid media such as BACTEC or MGIT growth is faster, 1-3 weeks.
- Nucleic acid amplification, such as the Xpert/RIF test, is useful at the initial stage only, since it frequently remains positive despite treatment through detection of dead organisms. It also detects rifampicin resistance.
Baseline blood tests are FBC, CRP, ESR, U&E and LFTs.
It is suspected based on the clinical presentation: a cough of more than 2 to 3 weeks' duration, lymphadenopathy, fevers, night sweats, weight loss; and a history of prior TB infection or disease, known or possible TB exposure, and past or present residence in or travel to an area where TB is endemic.
And before treatment begins, LFT and RFT should be done in all patients.
How it is treated
Standard treatment is 6 months for all patients with new-onset pulmonary TB and non-CNS extrapulmonary TB: an initial intensive phase of 2 months of isoniazid, rifampicin, pyrazinamide and ethambutol, then a continuation phase of isoniazid and rifampicin for the next 4 months. Where there are high levels of isoniazid resistance in new patients, or where isoniazid drug susceptibility testing is not done before the continuation phase begins, the continuation phase is 4 months of HRE instead. CNS TB is treated for 12 months.
Doses are isoniazid 200-300 mg/day (5 mg/kg/day), rifampicin 450-600 mg/day (10 mg/kg/day), pyrazinamide 20-30 mg/kg/day, ethambutol 10-25 mg/kg/day and streptomycin 1 gm I.M daily. Pyridoxine (vitamin B6) 10mg/d is given to prevent polyneuropathy, and it is also stated that pyridoxine is not required unless subjects are at higher risk of pyrazinamide-related peripheral neuropathy in diabetes, renal failure, HIV and alcoholics. Corticosteroids are recommended in CNS meningeal disease, pericardial effusion, pleural effusion and TB of the ureter, and in children with endobronchial disease.
Most patients can be treated at home; admission with appropriate isolation is considered for uncertainty about the diagnosis, intolerance of medication, adverse social conditions, or significant risk of MDR-TB. Where drug resistance is not anticipated, patients are assumed non-infectious after 2 weeks of therapy.
Effectiveness is assessed by further sputum smear at 2 months and at 5 months. Treatment failure is a positive sputum smear or culture at 5 months, or any patient with a multidrug resistant strain whether smear-positive or negative. Rifampicin may cause asymptomatic hyperbilirubinaemia, and with isoniazid and pyrazinamide may also cause hepatitis, though hepatotoxicity only occurs in 2-5%. Treatment is stopped to let symptoms subside and LFTs recover, and less hepatotoxic regimens are streptomycin, ethambutol and fluoroquinolone.
Set out as treatment principles, the regimen has a shape before it has drugs.
- Antituberculous regimens consist of two phases: an intensive phase, two months, followed by a continuation phase, four to seven months.
- Two effective drugs should be used at all times, and in the initial phase, the first 2 months, at least three effective drugs are recommended.
- Treatment should be guided by the results of drug sensitivity testing.
- Individual case management with directly observed therapy, DOT, is preferred for all patients, to ensure adherence and prevent emergence of drug resistance.
So the man started on antituberculous therapy is on an intensive phase of two months. The continuation phase after it is written as four to seven months here against the four months above, and both stand as written.
Extrapulmonary disease follows the same clock with two exceptions: the choice and duration of antituberculous therapy for extrapulmonary TB is the same as for pulmonary TB, with the exception of central nervous system disease, 12 months of therapy, and bone and joint disease, 6 to 9 months of therapy. Adjunctive corticosteroids are warranted in patients with tuberculous meningitis and constrictive pericarditis.